Archives of Medical Research
Volume 40, Issue 6 , Pages 471-477 , August 2009

Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV

  • Vicente Madrid-Marina

      Affiliations

    • Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
    • ,
  • Kirvis Torres-Poveda

      Affiliations

    • Centro de Investigación sobre Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Cuernavaca, Morelos, México
    • ,
  • Gabriela López-Toledo

      Affiliations

    • Programa de Doctorado en Ciencias Biomédicas, Universidad Nacional Autónoma de México, México, D.F., México
    • Laboratorio de Virus y Cáncer, Unidad de Investigación Biomédica en Cáncer, División de Investigación Básica, Instituto Nacional de Cancerología, SSa, México, D.F., México
    • ,
  • Alejandro García-Carrancá

      Affiliations

    • Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, México, D.F., México
    • Laboratorio de Virus y Cáncer, Unidad de Investigación Biomédica en Cáncer, División de Investigación Básica, Instituto Nacional de Cancerología, SSa, México, D.F., México
    • Corresponding Author InformationAddress reprint requests to: Alejandro García Carrancá, Laboratorio de Virus y Cáncer, División de Investigación Básica, Instituto Nacional de Cancerología, Avenida San Fernando No. 22, Colonia Sección XVI, Tlalpan, 14080, Mexico City, Mexico; Phone: (+52) (55) 56280433; FAX: (152) (55) 55734651

Received 6 July 2009 ,Accepted 13 July 2009.

References 

  1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–19
  2. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–527
  3. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women. Int J Cancer. 2002;102:519–525
  4. Bosch FX, Manos MM, Muñoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995;87:796–802
  5. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–428
  6. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(suppl 10):K1–K16
  7. Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058–2063
  8. FDA. Product approval information—licensing action [package insert]. Gardasil (quadrivalent human papillomavirus types 6,11,16,18). 2007 29/06/2009]; Available at: http://www.fda.gov/cber/label/HPVmer060806LB.pdf
  9. Cervarix® U.S. regulatory update. 30 March 2009 [cited 2009 June 29] (available at: <http://www.gsk.com/media/pressreleases/2009/2009_pressrelease_10038.htm)
  10. EPARs for authorised medicinal products for human use. December 2008 [cited 2009 July 8] Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/cervarix/cervarix.htm.
  11. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–1765
  12. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645–1651
  13. Zhou J, Sun XY, Stenzel DJ, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991;185:251–257
  14. Kirnbauer R, Booy F, Cheng N, et al. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA. 1992;89:12180–12184
  15. Viscidi RP, Kotloff KL, Clayman B, et al. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol. 1997;4:122–126
  16. Stanley M. Prophylactic HPV vaccines: preclinical and proof of principle studies. In:  Stern PL,  Kitchener HC editor. Vaccines for the Prevention of Cervical Cancer. Oxford: Oxford Oncology Library; 2008;p. 67–75
  17. Evans TG, Bonnez W, Rose RC, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183:1485–1493
  18. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol. 1995;69:3959–3963
  19. Suzich JA, Ghim SJ, Palmer-Hill FJ, et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA. 1995;92:11553–1157
  20. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571–5583
  21. De Carvalho N, Roteli-Martins C, Teixeira J, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvant vaccine up to 7.3 years. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  22. Rowhani-Rahbar A, Mao C, Alvarez FB, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  23. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–1255
  24. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459–1466
  25. Joura EA, Kjaer SK, Wheeler CM. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26:6844–6851
  26. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564–571
  27. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931–4939
  28. Hepburn HM, Seipel M, Scharz TF, et al. Ex-vivo monitoring of memory T-cells four years after vaccination. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  29. Fraser C, Tomassini JE, Xi L, et al. Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine. Vaccine. 2007;25:4324–4333
  30. Kitchener HC. Prophylactic HPV vaccination: current status. In:  Stern PL,  Kitchener HC editor. Vaccines for the Prevention of Cervical Cancer. Oxford: Oxford Oncological Library; 2008;p. 77–89
  31. Schiller JT, Castellsagué X, Villa LL, et al. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine. 2008;26(suppl 10):K53–K61
  32. Dillner J. Quadrivalent HPV (types 6/11/16/18) vaccine efficacy against low-grade genital desease. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  33. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–2170
  34. Paavonen J, Naud P, Salmerón J, et al. Final phase III efficacy analysis of cervarix in young women. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  35. Future II study group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915–1927
  36. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278
  37. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928–1943
  38. de Sanjosé S, Alemany L, Castellsagué X, et al. Human papillomavirus vaccines and vaccine implementation. Womens Health (Lond Engl). 2008;4:595–604
  39. Andrus JK, Sherris J, Fitzsimmons JW, et al. Introduction of human papillomavirus vaccines into developing countries—international strategies for funding and procurement. Vaccine. 2008;26(suppl 10):K87–K92
  40. Cuzick J, Arbyn M, Sankaranarayanan R, et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine. 2008;26(suppl 10):K29–K41
  41. Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine. 2001;19:1783–1793
  42. Fleury MJ, Touzé A, Alvarez E, et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol. 2006;151:1511–1523
  43. Skinner RAD, Chow SN, Wheeler C, et al. Cross-protective efficacy of Cervarix against oncogenic HPV types beyond HPV-16/18. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  44. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis. 2009;199:936–944
  45. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926–935
  46. Herrero R. Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. J Infect Dis. 2009;199:919–922
  47. Beller U, Abu-Rustum NR. Cervical cancer after human papillomavirus vaccination. Obstet Gynecol. 2009;113:550–552
  48. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201–209
  49. Centers for Disease Control and Prevention (CDC). Syncope after vaccination–United States, January 2005–July 2007. MMWR Morb Mortal Wkly Rep. 2008;57:457–460
  50. Brotherton JM, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. CMAJ. 2008;179:525–533
  51. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–24
  52. WHO. WHO Papillomavirus Position Paper. Weekly Epidemiological Record. 2009;84:37–40
  53. Winkler JL, Wittet S, Bartolini RM, et al. Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean. Vaccine. 2008;26(suppl 11):L73–L79
  54. Lazcano-Ponce E, Salmerón-Castro J, García-Carrancá A, et al. Recomendaciones para la definición de la política de vacunación contra el virus del papiloma en México. Salud Publica Mex. 2009;51:336–341
  55. Paavonen J, ed. Final phase III efficacy analysis of Cervarix in young women. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.
  56. Dillner J, ed. HPV vaccines trials and results. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malmö, Sweden.

PII: S0188-4409(09)00143-X

doi: 10.1016/j.arcmed.2009.08.005

Archives of Medical Research
Volume 40, Issue 6 , Pages 471-477 , August 2009

Article Tools